Cytek BioSciences, which provides cell analysis instruments for life science applications, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Cytek Biosciences' core products are the Aurora and Northern Lights systems, which are full spectrum flow cytometers that deliver high-resolution cell analysis by using the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells, also known as full spectrum profiling. As of March 31, 2021, the company has placed over 750 instruments to over 620 companies around the world, including pharmaceutical companies, over 125 biopharma companies, academic research centers, and clinical research organizations.
The Fremont, CA-based company was founded in 2014 and booked $99 million in sales for the 12 months ended March 31, 2021. It plans to list on the Nasdaq under the symbol CTKB. Cytek BioSciences filed confidentially on April 22, 2021. Morgan Stanley, Goldman Sachs, Piper Sandler, and Cowen are the joint bookrunners on the deal. No pricing terms were disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.